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Abstract
Background: The ability to expand virus- or tumor-specific T cells without damaging their functional capabilities is
critical for success adoptive transfer immunotherapy of patients with opportunistic infection or tumor. Careful
comparisons can help identify expansion methods better suited for particular clinical settings and identify recurrent
deficiencies requiring new innovation.
Methods: We compared the efficacy of magnetic beads coated with anti-CD3 and anti-CD28 (anti-CD3/CD28
beads), and soluble anti-CD3 plus mixed mononuclear cells (designated a rapid expansion protocol or REP) in
expanding normal human T cells.
Results: Both anti-CD3/CD28 beads and soluble anti-CD3 promoted extensive expansion. Beads stimulated greater
CD4 cell growth (geometric mean of 56- versus 27-fold (p < 0.01) at day 21) but both stimulated similar CD8
expansion (189- versus 186-fold). Phenotypically, bead-treated CD4 and CD8 T cells and anti-CD3-treated CD4 cells
typically assumed an effector/effector memory phenotype by day 14. By comparison, a subset of anti-CD3-treated
CD8 cells, derived from naïve cells, retained much greater expression of CD45RA, CD27 and CCR7, than matched
bead-treated cells despite comparable expansion. These cells were clearly distinguishable from CD45RA+ terminally
differentiated effector cells by the presence of CD27, the absence of CD57 and their inability to produce cytokines
after stimulation. When used to expand previously stimulated cells, anti-CD3 plus autologous MNCs produced
much less antigen-induced cell death of CD8 cells and significantly more CD8 expansion than beads.
Conclusions: Anti-CD3/CD28 beads are highly effective for expanding CD4 cells, but soluble anti-CD3 has
significant potential advantages for expanding CD8 T cells, particularly where preservation of phenotypically
“young” CD8 cells would be desirable, or where the T cells of interest have been antigen-stimulated in vitro or in
vivo in the recent past.
Background
With advances in the methods for selecting and manip-
ulating T cells there is increasing interest in the adop-
tive transfer of bioactive T cells as a treatment for
infections and cancer. This approach has been used suc-
cessfully to transfer antiviral immunity after stem cell
transplantation [1], and is under active investigation in
treating malignancy [2]. Antigen-specific T cells suitable
for transfer can only be retrieved from blood or tissue
sites in relatively small numbers, consequently they
usually are expanded specifically or nonspecifically prior
to transfer. Such ex vivo manipulations, however, poten-
tially can damage T cell homing, proliferation, and sur-
vival after infusion [3,4]. Given this risk, the choice of
methods may have important implications for clinical
efficacy.
Antibodies against CD3 are a central element in many
T cell proliferation protocols. Immobilized on a surface,
anti-CD3 delivers a strong proliferative signal through
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of additional costimulatory signals (signal 2), the result-
ing proliferation is often followed by premature T cell
apoptosis or anergy [5]. By immobilizing anti-CD3 and
anti-CD28 to simultaneously deliver signal 1 and a costi-
mulatory signal 2, proliferation can be increased without
provoking early cell death [6]. The expanding cells also
demonstrate enhanced ability to release cytokines and
lyse targets cells in an MHC unrestricted manner [7].
Consequently, magnetic beads coated with anti-CD3
and anti-CD28 (anti-CD3/CD28 beads) have proved a
convenient reagent for expansion which has been used
experimentally to boost T cell immunity in immunosup-
pressed cancer patients [8-10] and enhance the anti-
tumor effect of donor lymphocyte infusions after
allotransplantation [11]. These studies have established
that beads can be used to expand functional T cells, and
that some of these cells can persist in vivo postinfusion.
While these results are encouraging, the bead expan-
sion technique has limitations. Ex vivo expansion stimu-
lates the generation of effector T cells with increased
lytic and cytokine producing capability [7], but the capa-
city of these cells for additional homing and prolifera-
tion after infusion is uncertain [3]. While CD4 cells
respond very well to anti-CD3/CD28 stimulation, CD8
cells proliferate less extensively with an increased rate of
apoptosis [12]. Given the importance of CD8 T cells in
the anti-tumor response, this is a significant concern.
One commonly used alternative approach for stimu-
lating proliferation is the incubation of T cells with
soluble anti-CD3 antibody in the presence of Fc recep-
tor bearing accessory cells [13-15], an approach desig-
nated the “Rapid Expansion Protocol” (REP). Antibody
“presented” to T cells in this manner clearly generates a
more effective proliferative signal than soluble anti-CD3
alone or anti-CD3 immobilized on a plastic surface [16].
This presumably reflects the dual benefit of more exten-
sive anti-CD3-T cell receptor crosslinking on a surface,
and the costimulation provided by cell-cell interaction
between T cells and Fc receptor positive accessory cells
such as monocytes which constitutively express CD80
[17], CD86 [17], and CD137 [18]. These complex inter-
actions in some respects mimic events during physiolo-
gic antigen presentation. Given its efficacy, this
approach has been used extensively for expansion of
T cell clones and lines for in vitro and clinical adoptive
transfer studies [13-15,19].
To gain further insight into the similarities and differ-
ences between the T cell responses produced by beads
and REP, the current studies critically compare their
impact on T cell survival, proliferation, and phenotype.
While both beads and anti-CD3 are effective in expanding
T cells, our studies demonstrate substantial differences in
their impact on CD8 cells that merit consideration in
situations where preservation of the CD8 T cell response
in important.
Methods
Antibodies, beads, and chemicals
CD45RA/FITC, CD45RA/PE, CD57/FITC, CD28/PE,
CD4/PerCP, CD8/PerCP, CD27/APC, brefeldin A, anti-
IFNg/FITC, anti-TNFa/PE, 7-Amino-Actinomycin D (7-
AAD), and appropriate isotype controls were purchased
from BD Biosciences. Anti-human CCR7-phycoerythrin
was obtained from R&D Systems. Biotinylated anti-CD3
and anti-CD28 antibodies were purchased from
eBioscience. Anti-CD3 (Orthoclone OKT3) was pro-
vided by Stephen Migueles (NIAID, Bethesda, MD).
Flow-Check Fluorospheres were purchased from Beck-
man Coulter. Streptavidin-labeled Dynabeads (M280)
and CD3/CD28 T cell expander beads were obtained
from Invitrogen. Carboxyfluorescein succinimidyl ester
(CFSE) was purchased from Molecular Probes (Eugene,
OR) and recombinant human IL-2 was purchased from
PeproTech (Rocky Hill NJ).
Preparation of anti-CD3/CD28 beads
To prepare antibody-coated beads of varying composi-
tion, streptavidin-labeled beads were coated with varying
mixtures of biotinylated anti-CD3 and anti-CD28 anti-
bodies. To this end, streptavidin-M280 beads were
washed once with sterile PBS/BSA and resuspended at
10-50 millions beads/ml. Preliminary dose response stu-
dies, using FITC-labeled anti-mouse IgG and flow cyto-
metry to monitor biotinylated antibody binding to
beads, established that beads were saturated by 100 ng
of biotinylated antibody/million beads. Consequently
this total immunoglobulin/bead ratio was routinely used
for bead coating. To vary the ratio of antibody coating
on beads equimolar solutions of anti-CD3 and anti-
CD28 were mixed at 1:0, 1:5, 1:10, 1:20, 1:40, 1:80, 2
1:160, and 0:1 ratios. Control beads were coated with
biotinylated IgG1 isotype. Coating was performed on a
rotator stand at room temperature for 2-3 hours. Beads
were then washed two times with filtered PBS/BSA,
once with complete medium, and then resuspended in
RPMI 1640 complete medium. Antibody coating was
performed as needed, but preliminary studies established
that beads could be stored 4°C for at least one week
without any change in potency. In selected studies,
T cells were also stimulated using commercially
prepared anti-CD3 and anti-CD28 coated beads (CD3/
CD28 T cell Expander, Invitrogen).
Flow cytometry
Flow cytometry was performed using a 4-color Facscali-
bur (BD biosciences). The standard phenotypic analysis
was performed at different time point using antibody
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analyzed using Flow-Jo software.
Human leukocyte acquisition and purification
Normal healthy donors gave informed consent to blood
donation or leukapheresis procedures performed as spe-
cified in clinical protocols approved by the Institutional
Review Board of the Clinical Center of the National
Institutes of Health. Mixed mononuclear cells (MNCs)
obtained by leukepheresis or prepared from buffy coats
using Ficoll-Paque density gradient centrifugation, were
cryopreserved, and thawed as previously described [20].
To prepare T cell subsets for selected experiments,
MNCs from freshly collected buffy coat cells were puri-
fied by negative selection using CD8
+ Memory T Cell
Isolation and CD8
+ Naive T Cell Isolation Kits pur-
chased from Miltenyi Biotech.
Monitoring T cell division and early expansion using CFSE
labeled cells
To monitor cells division and expansion during the early
days after stimulation, cells were CFSE-labeled and moni-
tored using methods described by Hawkins, et al. [21]. In
brief, to label cells, 2-5 × 10
7 mixed mononuclear cells or
cultured T cells maintained in RPMI 1640 containing
10% fetal calf serum plus 100 unit/ml penicillin, 100 ug/
ml streptomycin, and 2 mM glutamine (RPMI/FCS) were
incubated with 2 μMC F S Ea t3 7 ° Cf o r1 0m i n .C e l l s
were then washed three times to remove unbound CFSE,
resuspended in fresh RPMI/FCS, and incubated over-
night. Labeled cells were then distributed (50,000/well) in
a 96 well round bottom plate in wells also containing
anti-CD3/CD28 coated beads (three beads/cell), anti-
CD3 (30 ng/ml), or no additional stimulator. When using
anti-CD3 to re-treat previously stimulated cells, 100,000
irradiated MNCs (accessory cell:responder ratio of 2:1)
were also added as a source of Fc receptor positive acces-
sory cells suitable for “presentation” of anti-CD3 to T
cells. Fresh cells received IL2 (50 U/ml) on day 2. Resti-
mulated cells were maintained with 50 U/ml of IL2 from
day 1. Wells were fed with additional medium containing
IL2 at day 4 or 5 and every 2-3 days thereafter. With con-
tinued growth, the contents of wells were diluted 4 fold
into new wells with fresh medium and IL2 as needed to
prevent overcrowding.
To monitor cell growth, at selected time points after
stimulation, 10,000 calibrator beads/well (Flow-Check
Fluorospheres, Beckman Coulter, CA) were added to
wells along with PE labeled anti-CD4 or anti-CD8 anti-
bodies. The contents of the well were mixed, incubated
for one half hour, and then washed twice with PBS/
BSA (1%) before addition of 7-AAD to exclude dead
cells in flow cytometry analysis. All measurements of
cell composition and number were performed in
quadruplicate.
The absolute number of cells per well at each time
point was calculated based on the number of calibrator
beads and the number of viable cells detected per well
by flow cytometry using the formula:
The proportion of cells undergoing 0-6 divisions could
then be quantitated based on the pattern of CFSE fluor-
escence using Flo-Jo software, and the total number of
viable cells per well.
Bulk stimulation of T cells in vitro
To monitor cell phenotype and cell expansion over a 3
week period, fresh MNC or cells expanded previously
using anti-CD3/CD28 beads or anti-CD3 were cultured in
12 well plates (5 × 10
6 cells in 2 ml/well) with anti-CD3/
CD28 beads (three beads/cell), anti-CD3 (30 ng/ml), or
medium alone. Previously expanded cells restimulated
with anti-CD3 routinely also received irradiated autolo-
gous MNC (2 cells/responder) as a source of Fc receptor
positive accessory cells. Medium containing recombinant
human IL2 (50 units/ml) was added to freshly cultured
cells at day 2 and to restimulated cells throughout the pro-
cess. Beads were removed using a magnet on day 7 post
stimulation. Cell counts of freshly stimulated cells were
monitored at least twice weekly and cultures were fed
every other day with fresh RPMI/FCS and IL2, and trans-
ferred to flasks or frozen as needed to maintain cell num-
bers between 0.75 and 2 × 10
6/ml. Because of the
presence of irradiated autologous feeder cells in REP trea-
ted cells, viable cell counts were not used to monitor cell
growth in restimulated cultures until after day 7 by which
time no more viable irradiated cells were present.
Measurement of Intracytoplasmic cytokine Production
T cells harvested 14 days after stimulation with anti-
CD3/CD28 beads or soluble anti-CD3 were treated for 4
hours with phorbol myristate acetate (PMA, 35 nM) and
the calcium ionophore A23187 (0.5 μM) or with medium
alone in the presence of brefeldin (Golgiplug, BD
Bioscience). Cells were then incubated with anti-CD8
PerCP and CD27 APC for 30 minutes, fixed and permea-
bilized using Cytofix/cytoperm solution (BD Bioscience)
as recommended by the manufacturer, and stained intra-
cellularly using anti-IFNg FITC and antiTNFa PE. Dupli-
cate samples were stained with an appropriate isotype
control. Cytokine expression in treated and control cells
was then assessed using flow cytometry.
Statistics
Paired t-tests and nonparametric 2-tail Wilcoxon
matched pairs tests were performed using Graphpad
Prism Software.
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Time course for T cell response to stimulation
The CFSE-labeled CD4 and CD8 T cells in MNCs began
dividing 40-50 hours after stimulation with anti-CD3/
CD28 beads or soluble anti-CD3. CD8 cells divided
slightly more rapidly than CD4 cells, and there were no
consistent differences in early response to the two sti-
muli (Figure 1A and 1C). The number of viable cells at
hour 40 (just before proliferation began) was similar in
unstimulated, bead-stimulated, and anti-CD3-stimulated
wells indicating neither stimulus caused extensive early
activation-induced cell death (AICD) (Figure 1B and
1D). Consistent with the timing of cell division, expan-
sion in cell number in response to either stimulus was
delayed until 50-60 hours after stimulation.
To compare the expansion produced by anti-CD3/
CD28 beads and anti-CD3, we monitored changes in
cell number in bulk cultures over a 21-day period in 11
separate studies (Figure 2) and noted several persistent
trends. Consistent with the more rapid rate of early cell
division noted in Figures 1A and 1C, CD8 cells
expanded more rapidly than CD4 cells in response to
either stimulus. Focusing on CD4 cells, this subset
expanded more rapidly in response to beads than anti-
CD3 (Figure 2A) and this difference was statistically sig-
nificant at days 7, 14, and 21. There was a trend to
more rapid expansion of CD8 cells in response to anti-
CD3, particularly at days 7 and 14, but these differences
did not achieve statistical significance (Figure 2B). Con-
sistent with these reciprocal trends in CD4 and CD8
expansion, cultures stimulated with anti-CD3 accumu-
lated a significantly higher proportion of CD8 cells at all
three time points than matched bead-treated cultures
(Table 1).
These studies were performed with beads coated with
anti-CD3 and anti-CD28 at a ratio of 1:20 but similar
results were obtained using beads coated at ratios of 1:5,
and 1:80 and with commercially available T cell expan-
der beads (data not shown). Comparisons of expansion
produced by anti-CD3 at 30 and 300 ng/ml also yielded
essentially identical results (data not shown).
Phenotypic changes in T cells during in vitro expansion
Peripheral blood T cells are usually subclassified as
naïve (CD45RA+, CCR7+), central memory (CD45RA-,
CCR7+), effector memory (CD45RA-, CCR7-), or
Figure 1 Early time course of T cell division and expansion in response to anti-CD3/CD28 beads and soluble anti-CD3. CFSE-labeled
CD4 (A) and CD8 (C) cells began dividing 40-60 hours after exposure to beads (solid lines) or anti-CD3 (dashed lines), but divided minimally in
the absence of stimulation (2× solid lines). The number of stimulated and control CD4 (B) and CD8 (D) T cells remained comparable until about
60 hours after stimulation when measureable cell expansion began.
Li and Kurlander Journal of Translational Medicine 2010, 8:104
http://www.translational-medicine.com/content/8/1/104
Page 4 of 15effector cells (CD45RA+, CCR7-)[22]. Naïve cells also
express CD27 and CD28, which are both progressively
lost with post-thymic proliferation and “differentiation”
towards an effector phenotype [23-26]. To compare the
impact of beads and anti-CD3, the expression of these
markers on CD4 and CD8 cells was assessed before and
after 2-3 weeks of in vitro stimulation. The results from
one representative experiment are illustrated in Figure 3.
The phenotype of CD4 T cells was similarly affected
by exposure to beads or anti-CD3 (Figure 3A) with sub-
stantial reductions in the expression of CD45RA, CCR7,
and CD27. CD8 T cells, on the other hand, were
affected differently by beads and anti-CD3. By day 14,
CD45RA expression on bead-treated cells was markedly
reduced, but a substantial fraction of anti-CD3-treated
cells retained CD45RA expression (Figure 3B). This sub-
population was strongly CD27 positive, and (to a lesser
extent) CCR7 positive. The same pattern of CD45RA
and CD27 expression was seen at day 21, but CCR7
expression often diminished substantially by this time
point. On the other hand, bead-treated cells usually
retained a higher proportion of CD28 positive cells both
at day 14 and 21. The size of the CD45RA+, CD27+
subset of CD8 cells in anti-CD3-treated cultures varied
somewhat from donor to donor, but the underlying pat-
tern was qualitatively consistent.
To clarify the origin of the persistent CD45RA
+/CD27+ subset, we stimulated purified naïve and mem-
ory CD8 populations with anti-CD3/CD28 beads or
anti-CD3 plus irradiated MNCs as a source of FcR+
accessory cells. A substantial proportion of anti-CD3-
treated naïve CD8 cells maintained the CD45RA+,
CCR7+, CD27+ phenotype noted above, but much fewer
bead-treated cells demonstrated this phenotype (Figure
4A and 4C). Memory cells did not consistently differ in
their pattern of CD45RA and CD27 retention in
response to either stimulus (Figure 4B and 4C). Thus
the phenotypic differences noted in mixed populations
can be largely attributed to variations in the response of
naïve CD8 T cells to soluble anti-CD3 plus accessory
cells versus beads.
CD45RA expression on cultured T cells is a typical
characteristic of terminally differentiated effector T cells,
but unlike conventional effectors [22], the CD45RA+
CD8 T cells noted after anti-CD3 treatment were con-
sistently CD27+ (Figure 3) and CD57- (data not shown).
Effector T cells typically produce intracellular cytokines
within 4 hours after stimulation in vitro [22], but the
CD27+ anti-CD3-expanded CD8 cells (in contrast with
the CD27- cells in the same preparation) produced little
intracellular IFNg or TNFa in response to PMA/A23187
stimulation (Figure 5).
T cell response to restimulation
On occasion, the number of cells generated by one cycle
of T cell expansion may be insufficient for the desired
purpose, and further expansion would be desirable. To
compare impact of restimulation, cells previously
expanded using anti-CD3/CD28 beads were CFSE-
labeled 6 to 63 days later, and restimulated with fresh
anti-CD3/CD28 beads, anti-CD3 plus irradiated autolo-
gous MNCs, or, as a control, maintained in medium
Figure 2 Comparison of CD4 (A) and CD8 (B) expansion after
stimulation with anti-CD3/CD28 beads (squares) or anti-CD3
(triangles). Beads stimulated significantly greater CD4 expansion
than anti-CD3 (p values for statistical significance at each time point
is indicated at the top of each box). CD8 expansion was slightly
greater in response to anti-CD3 at 7 and 14 days, but this trend was
not statistically significant. The p values were calculated using the
Wilcoxon matched pairs test.
Table 1 % CD8 T cells in primary cultures at 7-21 days
after stimulation with anti-CD3/CD28 beads and OKT3
Day after Stimulation
Cells stimulated with: 71 4 2 1
Anti-CD3/CD28 beads 34.0 ± 6.8 (11)* 47.6 ± 6.3 (11) 48.9 ± 5.4 (9)
OKT3-treated 53.7 ± 7.0 (11) 68.0 ± 5.4 (11) 63.3 ± 4.4 (9)
P < 0.005 P < 0.005 P < 0.05
*The results represent the mean ± SE for matched pairs of cultures with the
number of experiments marked in parentheses. Paired t-test was used to
assess significance.
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showed an increased rate of division 40-50 hours post
stimulation (Figure 6A and 6C). Unlike fresh cells (Fig-
ure 1B and 1D), however, restimulated cells (particularly
those retreated with beads) often decreased in number
relative to control cells over the first 40 hours of culture
reflecting early AICD (Figure 7B and 7D).
The findings from 11 experiments comparing T cell
expansion 3-14 days after restimulation are summarized
in Figure 7. Despite the initial AICD in many cases,
Figure 3 Comparison of T cell phenotype 14 and 21 days after primary stimulation of MNCs with CD3/CD28 beads and soluble anti-
CD3. CD4 T cells (A) showed a similar pattern of changes in response to either stimulus, but CD8 cells (B) demonstrated significant differences
in phenotype. At comparable levels of expansion, anti-CD3 treated CD8 cells retained higher levels of CD45RA, CD27, and CCR7 expression than
anti-CD3/CD28 bead treated cells and bead-treated CD8 cells expressed higher levels of CD28.
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100 fold by day 7 (figure 7A). CD8 T cells incubated
with soluble anti-CD3 plus irradiated MNCs demon-
strated a similar pattern, but bead-treated CD8 cells
showed significantly less expansion at all 3 time points
(Figure 7B).
Although the gross expansion of restimulated cells in
some experiments (Figure 7) was comparable in
Figure 4 Comparison of the impact of anti-CD3/CD28 beads and soluble anti-CD3 plus irradiated MNCs on expansion by purified
naive (A) and memory (B) CD8 cells. Significant differences in the phenotype of expanded naïve T cells, but not in memory cells, were noted.
Panel C collates the results of 3 experiments quantitating changes in CD45RA, CCR7, CD27, and CD28 surface antigen (expressed as geometric
mean channel fluorescence) when naïve and memoryCD8 cells were expanded using beads (squares) or anti-CD3/MNCs(circles) for 14 days.
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(Figure 2), matched control cells also often expanded as
well. To distinguish true restimulation-dependent
growth from persistent expansion still attributable to
primary stimulation, we calculated the ratio of expan-
sion by stimulated cells/expansion by matched control
cells and plotted this as a function of the time interval
between first and second stimulation (Figure 8A-D).
These plots make two important points. First, the
expansion ratio for cells re-exposed to beads was almost
always less than 1 at day 3 poststimulation (Figure 8A
and 8C) reflecting AICD, and this effect was particularly
severe for CD8 cells. By comparison soluble anti-CD3-
treated cells seldom demonstrated this degree of early
cell loss. Second, early restimulation (less than 20 days
after primary stimulation) was associated with greater
early cell loss at day 3, and poor expansion at day 7
(Figure 8B and 8D). This was most striking for bead-
treated cells (particularly CD8 cells), but soluble anti-
CD3 stimulated cells showed a similar, albeit less
marked, trend. In these studies, only cells rested > 30
days between stimulations demonstrated substantial
expansion relative to control cells. In sum, these studies
emphasize that even when gross expansion is observed,
restimulation (particularly with beads) may actually
impede cell expansion.
While figures 5, 6, 7 focused on the responses of cells
initially expanded using anti-CD3/CD28 beads, analo-
gous studies performed using cells initially expanded
using soluble anti-CD3 gave qualitatively identical
results.
Comparison of T cell size after stimulation with anti-CD3/
CD28 beads or anti-CD3
To gain additional insight into the relative impact of
beads and anti-CD3 on cells, we serially monitored for-
ward scatter (a relative measure of cell size) in CD4 and
CD8 cells after stimulation and restimulation. CD4 and
CD8 T cell size increased in a similar manner after pri-
mary treatment with either stimulus (Figure 9A and 9B).
Cells restimulated with anti-CD3/CD28 beads however
increased in size more slowly and maintained a larger
size for a longer period than matched anti-CD3 treated
cells, even when they were expanding poorly. These dif-
ferences in size could not be simply explained by differ-
ences in IL2 feeding schedule or cell concentration
within flasks.
Impact of variations in bead coating with anti-CD3 and
CD28 on T cell responses to restimulation
To assess whether bead-mediated expansion could be
improved by modifying the ratio of anti-CD3 to anti-
CD28 coating, we restimulated cells with beads coated
using a variety of antibody ratios (Figure 10). Restimu-
lated CD4 cells expanded better (overlapping in efficacy
with anti-CD3 plus irradiated MNCs) in response to
beads coated using lower anti-CD3: anti-CD28 ratios.
CD8 cell expansion was also improved by reducing the
anti-CD3:anti-CD28 ratio but even using the most
lightly coated beads (or beads coated with anti-CD 28
alone), expansion remained substantially inferior to that
produced using anti-CD3/MNCs. The poor response of
CD8 cells to beads was not appreciably improved by
adding irradiated MNCs and sufficient beads to main-
tain a 3:1 bead to total cell ratio (data not shown).
Discussion
Anti-CD3/CD28 beads and soluble anti-CD3 both sti-
mulate extensive polyclonal expansion of human
Figure 5 Intracytoplasmic cytokine production by day 14 anti-
CD3 stimulated CD8 T cells stimulated for 4 hours with PMA/
A23187. By comparison to CD27- cells, the CD27+ subset produced
little intracytoplasmic (A) tumor necrosis factor (TNF-a) or (B)
interferon- g (IFN-g). Similar results were obtained in each of 4
studies.
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cant advantage in expanding CD4 cells and anti-CD3
demonstrates a trend towards more rapid early CD8 cell
expansion. Proliferation of anti-CD3 treated cells slows
after day 14, while bead-mediated proliferation typically
continues for more than 21 days. Judged solely by their
efficacy in promoting expansion, beads are more effec-
tive. Our studies, however, identify two qualitative dif-
ferences that may merit consideration in tailoring an
expansion method for any particular clinical situation.
First, beads and anti-CD3 have quite different effects
in restimulating CD8 T cells. AICD, mediated at least in
part through Fas/FasL interaction and activation of the
proapoptotic molecule BIM, is a well-described compli-
cation of T cell stimulation [27,28]. Although CD28
costimulation enhances expression of the anti-apoptotic
molecule BCL-XL, concurrent anti-CD3 and anti-CD28
signaling can promote CD8 apoptosis [12]. The current
studies demonstrate that previously stimulated CD8
cells are particularly susceptible to AICD and growth
retardation after bead exposure. This effect is not lim-
ited to cells previously exposed to beads. Cells initially
stimulated using soluble anti-CD3 or PHA (data not
shown) respond in the same manner. This sensitivity
persists even in cells rested for more than 3 weeks
between stimulations. This was not an isolated observa-
tion using one particular bead formulation. Similar
results were observed using commercially available
beads and “home-brew” beads anti-CD3 and anti-CD28
coated at a variety of ratios.
Soluble anti-CD3 used in conjunction with irradiated
MNCs to restimulate cells produced significantly less
AICD and more CD8 T cell growth. The difference was
particularly striking when CD8 T cells were retreated
before cells had “rested” sufficiently after primary stimu-
lation. While anti-CD3 might fail to increase the growth
rate of still expanding cells, it did not produce the strik-
ing AICD and extended growth retardation associated
with anti-CD3/CD28 beads.
The mechanism underlying this difference was not
addressed in these studies, but a variety of factors may
contribute. Judging by the differences in time course for
changes in cell size after restimulation (Figure 9), solu-
ble anti-CD3 generates a less pronounced and pro-
longed T cell perturbation in restimulated cells than
anti-CD3/CD28 beads. Equally important, Fc receptor
Figure 6 Early time course for expansion of bead-expanded T cells after restimulation 14 days later with anti-CD3/CD28 beads or
anti-CD3 plus irradiated MMCs. Restimulated CD4 (A) and CD8 (C) both divided more extensively in response to anti-CD3 (dashed lines) than
anti-CD3/CD 28 (solid lines), but this difference was more pronounced for CD8 cells. CD4 T cell expansion (C) was similar in response to either
stimulus, but CD8 T cells (D) expanded substantially more rapidly than anti-CD3/CD28 bead-treated cells.
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express not only the CD28 ligands CD80 and CD86,
but CD137L which can activate CD137 [18], another
potent costimulatory molecule for CD8 T cell expansion
[29]. After interaction with stimulated T cells, mono-
cytes binding anti-CD3 may express additional costimu-
latory molecules and cytokines as well, generating a
more complex costimulatory environment than an inert
antibody-coated bead. Whatever the specific signaling
events, the adverse impact of beads on activated CD8
cells can not be simply ameliorated by reducing the
concentration of anti-CD3 on the bead surface or by
the presence of irradiated autologous MNCs at the time
of restimulation.
Figure 7 Comparison of CD4 (A) and CD8 (B) growth when bead-treated T cells were restimulation with anti-CD3/CD28 beads
(squares) or anti-CD3/irradiated MMCs (triangles). T cell expansion was monitored using CFSE labeled cells and flow cytometry as described
in the methods. CD4 expansion was similar in response to either stimulus. By contrast, bead-treated CD8 cells expanded significantly less well
than anti-CD3-treated cells at all time points. The p values with obtain using the Wilcoxon matched pairs test are indicated at the top of each
box.
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previously activated CD8 T cells has important implica-
tions. A second round of stimulation with anti-CD3/
CD28 beads is a risky strategy for enhancing the yield of
antigen-specific cells. Any increase in absolute cell num-
ber must be balanced against damage to surviving cells
and unwanted pruning of the repertoire from AICD
before expansion. Equally important, if cells activated
physiologically behave like in vitro stimulated cells, T
cells responding to antigen in vivo (for example tumor-
specific CD8 T cells in tumor infiltrating lymphocytes
preparations or antiviral CD8 T cells retrieved from the
blood of a patient with active viral infection) may be
vulnerable to bead-induced AICD or growth retardation
during even an initial round of ex vivo stimulation. If
so, bead exposure may selectively damage or destroy an
important subset of harvested T cells. For this reason,
stimulation using soluble anti-CD3 plus MNCs may
deserve greater consideration as an alternative approach
for expanding of CD8 cells in situations where a desired
antigen-specific cell subset may have been “preactivated”
in vivo.
We also noted significant phenotypic differences
between the CD8 T cells expanded in response to beads
and soluble anti-CD3. Consistent with most [22,30,31],
but not all [32] prior studies of in vitro stimulated T
cells bead and soluble anti-CD3 treated CD4 cells and
bead-treated CD8 cells assume predominantly an effec-
tor or effector memory phenotype, markedly downregu-
lating CD45RA and CCR7 by day14 post stimulation. By
contrast, a subset of anti-CD3 treated CD8 cells retained
CD45RA, CD27, and, to lesser extent, CCR7 and CD28
expression at day 14. By studying purified CD8 subset
cells, we could establish that these phenotypically dis-
tinctive cells were derived from the naïve CD8 T cell
subset. The pattern of strong CD45RA expression in
cultured CD8 T cells, is often associated with terminally
differentiated effectors [22], but based on their deriva-
tion from naïve cells, the preservation of CD27, and
CCR7 (at week 2 with gradual disappearance by week
Figure 8 Evaluation of the interrelationship between the type and timing of the second stimulus and expansion of restimulated CD4
(A and B) and CD8 (C and D) T cells. To normalize for the impact of persistent growth attributable to primary stimulation, the ratio of growth
after restimulation to growth by matched control cells in the absence of restimulation was calculated. Regardless of the interval between
stimulations, by day 3, CD4 (A) and CD8 (B) cells re-incubated with anti-CD3/CD28 beads usually had a stimulation ratio of less than 1 i.e. cells
had diminished in number compared to control untreated cells. Even at day 7 (B and D), the stimulation ratio seldom exceeded 1 for cells
which had been rested in vitro between stimulations for less than 20 days. By comparison, the stimulation ratio for anti-CD3/MMC treated cells
seldom dropped below 1 at day 3, and increased further with time, even when the rest interval between stimulations was less than 14 days.
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lular cytokine production in response to restimulation,
we suggest these cells evolve towards a phenotype ana-
logous to the CD45RA+, CCR7-, CD27+ CD8 T cells
n o t e dp r e v i o u s l yi nh u m a nb l o o d[ 2 5 ] .T h i ss u b s e th a s
been shown to have a proliferative history and effector
function intermediate between naïve and effector mem-
ory cells.
The explanation for these differences in phenotypic
evolution of bead and soluble anti-CD3 stimulated cells
remains uncertain. Since CD45RA expression can be
reversibly downregulated in response to T cell receptor
stimulation [33], reduced expression of this antigen
could, in part, be explained by the prolonged duration
of bead-mediated stimulation noted in these and prior
studies [6]. The more prolonged impact of bead stimula-
tion could also contribute to reduced CD27 expression
by enhancing and sustaining expression of CD70, a nat-
ural ligand, which can downregulate CD27 expression
on stimulated T cells [34]. It is unlikely however, that
such reversible effects could fully explain CD45RA and
CD27 loss. Neither CD45RA nor CD27 were re-
expressed on bead-treated cells even after several weeks
after bead removal suggesting more durable differences
in CD8 T cell expression. Such divergence would not be
surprising since differences in the quality, magnitude,
and duration of T cells signaling have been well docu-
mented to influence T cell differentiation [35].
The functional properties of the CD45RA+ CD8 cells
produced during anti-CD3 mediated expansion merit
further study. Derived from naïve cells, these relatively
“young” cells retain expression of both CCR7, a crucial
receptor in lymphoid trafficking to central lymphoid tis-
sues for several weeks, and CD27, an antigen positively
associated with T cell proliferation in vitro and engraft-
ment after adoptive transfer in vivo [34,36] for even
longer despite substantial expansion. Cells with these
properties could have an advantage in trafficking into
and proliferating within central lymphoid tissues in vivo
compared to bead treated cells expressing an effector
phenotype. On the other hand, although these cells do
express more CD27 and CCR7, they also often express
less CD28 than comparable bead-treated cells, and
CD28 expression in some settings has been a surrogate
marker for proliferative potential and telomerase expres-
sion [37,38]. Clearly, additional in vitro and ultimately
in vivo function studies addressing the homing and pro-
liferative capacity of this subset would be needed to
accurately assess its properties.
Anti-CD3/CD28 coated beads and soluble anti-CD3
have each been used clinically to expand cells for adop-
tive transfer with promising results in some settings
[8-11,13-15,19]. While beads are extremely effective in
stimulating CD4 T cell expansion and in generating
bioactive effector cells, the current studies raise the pos-
sibility that soluble anti-CD3 may be a safer reagent for
Figure 9 Comparison of changes in forward scatter measured by flow cytometry (a measure of cell size) in response to anti-CD3/
CD28 beads and anti-CD3. Primary CD4 (A) and CD8 cells (B) showed similar changes in forward scatter after exposure to either stimulus, but
CD4 (C) and CD8 (D) cells restimulated on day 30 increased in size more slowly and remained large for longer after restimulation with beads.
This difference in size was noted even when the enlarged cells were expanding poorly.
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gen-stimulated. The findings also suggest this approach
may be more effective in preserving expression of func-
tionally important surface antigens such as CCR7 and
CD27 on naive T cells during expansion.
While these studies have focused broadly on the
expansion and phenotype of CD4 and CD8 T cell
populations, in practical applications it is the ability of
any given method to expand functionally active, anti-
gen-specific T cells directed against a defined target
pathogen or tumor that is most critical. Evaluating effi-
cacy in achieving this goal is more complicated parti-
cularly given the potential phenotypic heterogeneity of
antigen-specific populations. Whereas naturally occur-
ring melan A-responsive CD8 T cells are predomi-
nantly naïve in phenotype [39], EBV-specific CD8 cell
populations contain a high proportion of effector
memory cells, and CMV-specfic responses are often
dominated by effector CD8 T cells [40,41]. These dif-
ferences in phenotype and biology may substantially
shape how each antigen-specific population respond to
any given expansion protocol. Future studies systemati-
cally comparing the efficacy of anti-CD3/CD28 beads,
soluble anti-CD3, and potentially other expansion pro-
tocols in expanding defined populations of antigen-
specific naïve, memory, and effector T cells could be
helpful in beginning to develop more nuanced guide-
lines for selecting the best cell expansion method for
any particular clinical settings.
Looking to the future, with growing interest in using
adoptive transfer to treat human disease, many promis-
ing new approaches are under active study for improv-
ing T cell expansion. These include the use of other
cytokines as well as or instead of IL2 as growth factors,
tumor-derived cell lines engineered to express bioactive
costimulatory molecules and cytokines as accessory cells
[42], and retroviral or lentiviral vectors coding chimeric
antigen receptors to confer defined antigenic specificity
on T cells [42-44]. In judging the impact of these newer
approaches and cell products, the current studies defin-
ing the in vitro performance characteristics of “standard”
expansion protocols hopefully may serve as a useful
“measuring stick” with which to judge the value of new
approaches for stimulating and restimulating human T
cells.
Conclusions
Anti-CD3 in the presence of Fc receptor positive acces-
sory cells, is an effective method for expanding CD4 and
CD8 T cells which could have potential advantages over
anti-CD3/CD28 coated beads in expanding CD8 T cells
which may have been recently activated or antigen-
exposed in vitro or in vivo without provoking antigen
induced cell death. This method also may be advanta-
geous in maintaining CCR7 expression on expanding
CD8 cells in settings where central lymphoid trafficking
of adoptively transferred CD8 cells may be particularly
desireable.
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